AP3536A - Method of treating atrial fibrillation - Google Patents

Method of treating atrial fibrillation

Info

Publication number
AP3536A
AP3536A AP2012006331A AP2012006331A AP3536A AP 3536 A AP3536 A AP 3536A AP 2012006331 A AP2012006331 A AP 2012006331A AP 2012006331 A AP2012006331 A AP 2012006331A AP 3536 A AP3536 A AP 3536A
Authority
AP
ARIPO
Prior art keywords
atrial fibrillation
treating atrial
treating
fibrillation
atrial
Prior art date
Application number
AP2012006331A
Other languages
English (en)
Other versions
AP2012006331A0 (en
Inventor
Charles Antzelevitch
Luiz Belardinelli
Alexander Burashnikov
John Shryock
Dewan Zeng
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43736345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP3536(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AP2012006331A0 publication Critical patent/AP2012006331A0/xx
Application granted granted Critical
Publication of AP3536A publication Critical patent/AP3536A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
AP2012006331A 2009-12-21 2010-12-20 Method of treating atrial fibrillation AP3536A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28873909P 2009-12-21 2009-12-21
PCT/US2010/061257 WO2011084733A1 (en) 2009-12-21 2010-12-20 Method of treating atrial fibrillation

Publications (2)

Publication Number Publication Date
AP2012006331A0 AP2012006331A0 (en) 2012-06-30
AP3536A true AP3536A (en) 2016-01-13

Family

ID=43736345

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2012006331A AP3536A (en) 2009-12-21 2010-12-20 Method of treating atrial fibrillation

Country Status (36)

Country Link
US (3) US8513254B2 (zh)
EP (2) EP2749282B1 (zh)
JP (2) JP5723889B2 (zh)
KR (2) KR20160108611A (zh)
CN (3) CN104688739A (zh)
AP (1) AP3536A (zh)
AR (1) AR079552A1 (zh)
AU (1) AU2010339753B2 (zh)
BR (1) BR112012015499A2 (zh)
CA (1) CA2784028C (zh)
CL (1) CL2012001597A1 (zh)
CR (1) CR20120353A (zh)
CY (1) CY1116511T1 (zh)
DK (1) DK2515900T3 (zh)
EA (2) EA201691336A1 (zh)
EC (1) ECSP12012004A (zh)
ES (2) ES2646603T3 (zh)
HR (1) HRP20150644T1 (zh)
HU (1) HUE026916T2 (zh)
IL (1) IL220152A (zh)
ME (1) ME02179B (zh)
MX (2) MX344329B (zh)
NO (1) NO2749282T3 (zh)
NZ (2) NZ627181A (zh)
PE (1) PE20121520A1 (zh)
PL (2) PL2749282T3 (zh)
PT (2) PT2749282T (zh)
RS (1) RS54118B1 (zh)
SG (3) SG10201408528RA (zh)
SI (2) SI2749282T1 (zh)
SM (1) SMT201500171B (zh)
TW (1) TWI508726B (zh)
UA (1) UA109887C2 (zh)
UY (1) UY33119A (zh)
WO (1) WO2011084733A1 (zh)
ZA (1) ZA201204608B (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2523873T3 (es) 2002-05-21 2014-12-02 Gilead Sciences, Inc. Administración de un inhibidor parcial de la oxidación de ácidos grasos, tal como ranolazina, para el tratamiento de la diabetes
NZ598942A (en) 2009-07-27 2014-02-28 Gilead Sciences Inc Fused heterocyclic compounds as ion channel modulators
CN104873389B (zh) 2009-07-29 2017-12-05 Icu医学有限公司 流体传输装置及使用方法
WO2011135582A2 (en) * 2010-04-28 2011-11-03 Cadila Healthcare Limited Pharmaceutical compositions of dronedarone
NZ604478A (en) 2010-07-02 2014-12-24 Gilead Sciences Inc Fused heterocyclic compounds as ion channel modulators
PL2707361T3 (pl) 2011-05-10 2018-01-31 Gilead Sciences Inc Skondensowane związki heterocykliczne stosowane jako modulatory kanału sodowego
TWI549944B (zh) 2011-07-01 2016-09-21 吉李德科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (zh) 2011-07-01 2018-04-28
US20150045305A1 (en) * 2012-01-27 2015-02-12 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
WO2014179764A1 (en) * 2013-05-03 2014-11-06 Gilead Sciences, Inc. Method of treating atrial fibrillation
AU2014296378B2 (en) * 2013-08-02 2017-03-30 Gilead Sciences, Inc. Pharmaceutical compositions of ranolazine and dronedarone
EP3068440B1 (en) * 2013-11-15 2020-01-08 Northwestern University Inhibition of oxidative stress in atrial fibrillation
PT3083608T (pt) 2013-12-19 2018-11-09 Gilead Sciences Inc Compostos heterocíclicos fundidos como moduladores de canal iónico
CN104951870B (zh) * 2015-06-01 2018-11-13 南通科瑞斯生物医药科技有限公司 药物临床前心脏风险评估方法
US20190119236A1 (en) 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
CA3016081A1 (en) 2016-03-04 2017-09-08 Gilead Sciences, Inc. Compositions and combinations of autotaxin inhibitors
US10575744B2 (en) 2017-02-24 2020-03-03 Medtronic Cryocath Lp Pericardial balloon mapping
US10799703B2 (en) * 2017-12-22 2020-10-13 Medtronic, Inc. Evaluation of his bundle pacing therapy
EP3530182B1 (en) * 2018-02-27 2020-12-09 Nokia Technologies Oy Apparatus and method for determining a change in left ventricular twist of a subject's heart
TWI814350B (zh) * 2018-07-16 2023-09-01 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
JP7588414B2 (ja) * 2019-01-24 2024-11-22 ノースウエスタン ユニバーシティ 心房細動の遺伝子療法による治療
AU2022403012B2 (en) 2021-12-03 2026-02-12 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
SI4440702T1 (sl) 2021-12-03 2025-09-30 Gilead Sciences, Inc. Terapevtske spojine za okužbo z virusom hiv

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009150535A1 (en) * 2008-06-10 2009-12-17 Sanofi-Aventis Dronedarone for the prevention of permanent atrial fibrillation

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
DE69034000T2 (de) 1989-06-23 2003-06-05 Syntex (U.S.A.) Llc, Palo Alto Ranolazin und verwandte Piperazine zum Schutz der Skelettmuskulatur
FR2665444B1 (fr) 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
ZA953078B (en) 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
FR2764800B1 (fr) 1997-06-23 1999-09-10 Sanofi Sa Composition pharmaceutique solide contenant des derives de benzofuranne
US6303607B1 (en) 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
JP2004505061A (ja) 2000-07-27 2004-02-19 ファルマシア・コーポレーション うっ血性心不全の処置のための、エポキシ−ステロイド型アルドステロン拮抗薬とカルシウムチャンネル遮断薬の併用療法
FR2817750B1 (fr) 2000-12-11 2003-02-21 Sanofi Synthelabo Composition pharmaceutique de dronedarone pour administration parenterale
ATE319423T1 (de) 2000-12-27 2006-03-15 Genzyme Corp Kontrollierte freisetzung von anti-arrhythmica aus einem biodegradierbaren hydrogel für die lokale anwendung am herzen
CN1533274A (zh) 2001-07-20 2004-09-29 �����ɷ� 苯并呋喃和其在治疗房性纤维颤动中的应用
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US7772232B2 (en) 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
JP2008526879A (ja) 2005-01-06 2008-07-24 シーブイ・セラピューティクス・インコーポレイテッド ラノラジンを含有する徐放性薬学的処方物
WO2007053610A2 (en) 2005-11-01 2007-05-10 The Regents Of The University Of California Methods of treating atrial fibrillation wtih pirfenidone
WO2008100992A1 (en) 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Intravenous solutions comprising ranolazine
US20090247535A1 (en) 2008-03-26 2009-10-01 Duke University Use of ranolazine for non-cardiovascular disorders
WO2010028173A2 (en) 2008-09-04 2010-03-11 Gilead Palo Alto, Inc. Method of treating atrial fibrillation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009150535A1 (en) * 2008-06-10 2009-12-17 Sanofi-Aventis Dronedarone for the prevention of permanent atrial fibrillation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANTZELEVITCH C. et al., "Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation", Journal of Electrocardiology, 1 November 2009, Vol. 42, No. 6, pages 543-548 *
FOR THE ERATO STUDY INVESTIGATORS ET AL: "Dronedarone for the control of ventricular rate in permanent atrial fibrillation: The Efficacy and safety of dRonedArone for The cOntrol of ventricular rate during atrial fibrillation (ERATO) study", AMERICAN HEART JOURNAL, vol. 156, no. 3, September 2008 (2008-09-01), MOSBY- YEAR BOOK INC, US, pages 527.E1 - 527.E9, XP025470440 *
GRAMLEY FELIX ET AL: "Recent advances in the pharmacological treatment of cardiac arrythmias.", DRUGS OF TODAY, vol. 45, no. 11, November 2009 (2009-11-01), BARCELONA, SPAIN, pages 807 - 824, XP002631257 *
KUMAR KAPIL ET AL: "New and emerging antiarrhythmic drugs for atrial fibrillation: what may become available to the clinician in the near future.", CURRENT TREATMENT OPTIONS IN CARDIOVASCULAR MEDICINE, vol. 11, no. 5, October 2009 (2009-10-01), pages 373 - 380, XP002631255 *
SCIRICA BENJAMIN M ET AL: "Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of Arrhythmias in patients with Non-ST-Segment-Elevation acute coronary syndrome - Thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) Randomized controlled trial", CIRCULATION, vol. 116, no. 15, October 2007 (2007-10-01), pages 1647 - 1652, XP002631256 *

Also Published As

Publication number Publication date
PT2749282T (pt) 2017-11-15
PL2515900T3 (pl) 2015-10-30
CN102665713A (zh) 2012-09-12
US8754087B2 (en) 2014-06-17
AP2012006331A0 (en) 2012-06-30
SMT201500171B (it) 2015-09-07
EP2749282A1 (en) 2014-07-02
SG10201408528RA (en) 2015-04-29
SG181541A1 (en) 2012-07-30
US9056108B2 (en) 2015-06-16
AU2010339753B2 (en) 2015-01-22
IL220152A0 (en) 2012-07-31
SI2515900T1 (sl) 2015-07-31
EP2515900A1 (en) 2012-10-31
JP2015057449A (ja) 2015-03-26
CN102665713B (zh) 2015-02-18
NZ600718A (en) 2014-08-29
RS54118B1 (sr) 2015-12-31
US20130317038A1 (en) 2013-11-28
ME02179B (me) 2015-10-20
KR20120107995A (ko) 2012-10-04
PT2515900E (pt) 2015-07-30
NO2749282T3 (zh) 2018-01-06
US8513254B2 (en) 2013-08-20
UY33119A (es) 2011-07-29
PL2749282T3 (pl) 2018-01-31
CL2012001597A1 (es) 2013-06-28
UA109887C2 (uk) 2015-10-26
US20140323493A1 (en) 2014-10-30
CA2784028A1 (en) 2011-07-14
AU2010339753A1 (en) 2012-07-12
CN104688739A (zh) 2015-06-10
US20110183990A1 (en) 2011-07-28
CN104147010A (zh) 2014-11-19
MX344329B (es) 2016-12-13
WO2011084733A1 (en) 2011-07-14
JP5723889B2 (ja) 2015-05-27
TW201136586A (en) 2011-11-01
ES2646603T3 (es) 2017-12-14
EA201691336A1 (ru) 2017-05-31
MX2012007052A (es) 2012-07-30
JP2013515007A (ja) 2013-05-02
IL220152A (en) 2016-11-30
EA201290451A1 (ru) 2013-01-30
ZA201204608B (en) 2013-02-27
BR112012015499A2 (pt) 2016-05-03
HRP20150644T1 (hr) 2015-07-31
EP2749282B1 (en) 2017-08-09
PE20121520A1 (es) 2012-11-26
SG10201710751TA (en) 2018-02-27
SI2749282T1 (sl) 2017-12-29
HUE026916T2 (en) 2016-08-29
ECSP12012004A (es) 2012-08-31
CR20120353A (es) 2014-10-07
KR20160108611A (ko) 2016-09-19
CA2784028C (en) 2016-08-23
AR079552A1 (es) 2012-02-01
HK1170675A1 (zh) 2013-03-08
EA025445B1 (ru) 2016-12-30
TWI508726B (zh) 2015-11-21
DK2515900T3 (en) 2015-07-27
CY1116511T1 (el) 2017-03-15
NZ627181A (en) 2016-02-26
EP2515900B1 (en) 2015-04-29
ES2540093T3 (es) 2015-07-08

Similar Documents

Publication Publication Date Title
AP3536A (en) Method of treating atrial fibrillation
EP2558014A4 (en) Methods and devices for treating atrial fibrillation
EP2421607A4 (en) DEVICE AND METHOD FOR PROOFING AND TREATING PREVIOUS LAYOUMS
ZA201006648B (en) Methods of treatment
EP2313103A4 (en) PROCESS FOR TREATING A BLÉPHARITE
IL214664A0 (en) Methods of treating hair related conditions
GB201018147D0 (en) Method of treatment
PL2501381T3 (pl) Leczenie migotania przedsionków
GB201003920D0 (en) Method of treatment
EP2300496A4 (en) ATHEROSCLEROSIS TREATMENT METHODS
ZA201108493B (en) Method of treating hair
ZA201005206B (en) Method of treating hair
GB201018149D0 (en) Method of treatment
EP2585103A4 (en) METHOD OF TREATMENT
IL216456A0 (en) Method of treating frailty
GB201020015D0 (en) Method of treatment
EP2424539A4 (en) PROCESS FOR TREATING DEPRESSION
EP2306838A4 (en) METHOD FOR THE TREATMENT OF ATHEROSCLEROSIS
HK1158972A (zh) 治療心房纖氈的方法
AU2011904917A0 (en) Method for preventing and/or treating atrial fibrillation
HK1182299A (zh) 用於治療心房顫動的方法和裝置
GB0823435D0 (en) Method of treatment
GB0909807D0 (en) Method of treatment
GB0921823D0 (en) Method of treatment
GB0904164D0 (en) Method of treatment